[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Instituto Valenciano de Infertilidade de Lisboa\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":139},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,56,92,119],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100628788","phase-4-exogenous-progesterone-as-ovulation-trigger-100628788",false,"NCT07466199","Exogenous Progesterone as Ovulation Trigger","Exogenous Progesterone as Ovulation Trigger - a Pilot Study","PRO-TRIGGER","Inclusion Criteria:\n\n* Informed Consent Form dated and signed correctly prior to the performance of any study procedure.\n* Oocyte donors aged \\>17 and \\\u003C34 years old in the moment of the recruitment.\n* Patients with regular menstrual cycles (between 25 to 35 days long).\n* Generally healthy women with no history of endocrine disorders (e.g., polycystic ovary syndrome (PCOS) or significant systemic disease).\n* Body Mass Index (BMI) between 18.5 and 28.\n\nExclusion Criteria:\n\n* Presence of ovarian cyst(s) detected on the baseline (initial) ultrasound examination.\n* Untreated endocrine conditions (polycystic ovary syndrome (PCOS), uncontrolled thyroid dysfunction and hyperprolactinemia).\n* Hypogonadotropic or hypergonadotropic hypogonadism.\n* Known hypersensitivity or clinical contraindication to the administration of vaginal progesterone or its excipients. This includes, but is not limited to: active deep vein thrombosis or thromboembolic disorders, known or suspected estrogen- or progesterone-dependent neoplasia, undiagnosed abnormal genital bleeding, porphyria, or severe hepatic dysfunction. Additionally, patients with anatomical abnormalities of the vagina that preclude the proper insertion or absorption of the vaginal insert are excluded.\n* Any condition contraindicating vaginal ultrasound and\u002For vaginal oocyte retrieval.These include: active pelvic inflammatory disease (PID), acute vaginal or cervical infection, or presence of pelvic malignancies. Patients with significant anatomical distortions or vascular anomalies in the pelvic region that, in the investigator's opinion, would make oocyte retrieval technically unfeasible or pose an unacceptable risk of hemorrhage or injury to adjacent organs, are also excluded.\n* Use of hormonal contraceptives (oral, patch, or ring) or GnRH analogues within the month preceding the study. Note: Participants who have discontinued these or other prohibited medications for a period of at least 30 days are eligible for rescreening starting at Visit 1.\n* Participation in any other ongoing clinical trial or use of investigational drugs within the last 30 days.","FEMALE","18 Years","33 Years",{"count":21,"type":22},10,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The goal of this clinical trial is to learn whether the sudden administration of vaginal micronized progesterone during the late follicular phase can trigger an LH surge and reactivation of oocyte meiosis in healthy oocyte donors aged 18 to 33 undergoing a mild ovarian stimulation cycle. The main question it aims to answer is:\n\n* Does progesterone administered in the late follicular phase induce an LH surge and subsequent oocyte meiosis reactivation?\n\nParticipants will:\n\n* Undergo a mild ovarian stimulation with 75 IU of follitropn alfa\n* Start vaginal micronized progesterone (400 mg every 12 hours) once at least one follicle reaches 15 mm\n* Have blood samples collected to measure hormone levels before and after progesterone administration\n* Undergo oocyte retrieval 35-36 hours after the progesterone trigger\n\nThis is a low-intervention, single-center pilot study including approximately 10 oocyte donors.",[28,29,30,31,32],"Ovulation","Ovarian Function","Assisted Reproductive Treatments","Oocyte Maturation","Hormonal Response",[34,35,36,31,37,38,39,40,41,42],"Trigger","Oocyte Donation","Progesterone","Luteinizing Hormone","LH Surge","Oocyte Retrieval","Oocyte Meiosis","Late Follicular Phase","Endocrinological profile","NOT_YET_RECRUITING","2026-06-02",{"date":46,"type":47},"2026-06-04","ACTUAL",{"date":49,"type":22},"2026-07",{"date":51,"type":22},"2026-08",{"name":53,"class":54},"Instituto Valenciano de Infertilidade de Lisboa","NETWORK",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":64,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":68,"conditions":69,"keywords":74,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":55},"100628459","comparison-of-two-vaginal-progesterone-forms-in-frozen-embryo-transfer-100628459","NCT07461909","Comparison of Two Vaginal Progesterone Forms in Frozen Embryo Transfer","Comparison of Patient Satisfaction, Convenience and Tolerability Between Two Vaginal Progesterone Formulations During Frozen Embryo Transfer","COPS","Inclusion Criteria:\n\n* Age: ≥18 and \\\u003C49 years old;\n* Body Mass Index (BMI) ≥18.5 Kg\u002Fm2 and \\\u003C30 Kg\u002Fm2;\n* Planned for single blastocyst stage transfer;\n* Has been prescribed two vaginal 200mg soft capsules or one 400mg pessary of progesterone, each 12hours before and after FET;\n* Either AC-FET or NPP-FET.\n\nExclusion Criteria:\n\n* Women who have previously enrolled in this study;\n* Those unable to comprehend the investigational nature of the proposed study;\n* Rank of FET\\>3;\n* Use of oral\u002Finjectable corticoids.","48 Years",{"count":66,"type":22},400,"OBSERVATIONAL","The goal of this observational study is to compare two commonly used vaginal progesterone formulations - soft capsules versus pessaries - in women undergoing frozen embryo transfer (FET). The main question it aims to answer is:\n\n\\- Do soft vaginal progesterone capsules provide similar or better patient satisfaction, convenience, and tolerability compared with vaginal progesterone pessaries during preparation for frozen embryo transfer?\n\nParticipants undergoing FET who are prescribed vaginal progesterone as part of their endometrial preparation and luteal phase support will use one of the two formulations and complete patient-reported assessments regarding satisfaction, convenience, and tolerability. The study will also measure serum progesterone levels on the day of embryo transfer and evaluate pregnancy outcomes, including clinical pregnancy and live birth rates.",[70,71,72,73],"Frozen Embryo Transfer (FET)","Infertility","Artificial Cycle","Natural Cycle",[36,75,76,77,78,79,80,81,82],"Natural cycle","Natural proliferative phase (NPP-FET)","Artificial cycle (AC-FET)","Patient satisfaction","Frozen embryo transfer","Assisted reproduction","Endometrial preparation","Treatment tolerability","RECRUITING","2026-03-06",{"date":86,"type":47},"2026-03-10",{"date":88,"type":47},"2024-11-08",{"date":90,"type":22},"2026-12",{"name":53,"class":54},{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":99,"minAge":18,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":103,"conditions":104,"keywords":107,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":118,"locationsCount":55},"100599644","ai-driven-model-impact-on-patient-engagement-in-medically-assisted-reproduction-100599644","NCT07087171","AI-Driven Model Impact on Patient Engagement in Medically Assisted Reproduction","Assessing the Impact of an Artificial Intelligence-Machine Learning Model on Patient Engagement in Medically Assisted Reproduction","Inclusion Criteria:\n\n* Infertile patients aged 18-45 years\n* Patients willing to undergo Medically Assisted Reproduction (heterosexual couples, same-sex female couples and single females undergoing artificial insemination, IVF\u002FICSI or oocyte donation treatments)\n\nExclusion Criteria:\n\n* Age \\>45 years\n* Patients who are not candidates for IVF\u002FICSI\n* Patients who are menopausal or peri-menopausal\n* Patients undergoing Fertility Preservation\n* Same-sex couples who will undergo reception of oocytes from partner.\n* Patients who decline to be counselled about their probability of having a live birth from IVF\u002FICSI treatment","ALL","45 Years",{"count":102,"type":22},774,"Infertility is a globally significant medical condition, profoundly impacting individuals and couples both emotionally and physically. The multifaceted nature of in vitro fertilization (IVF) treatment demands active patient participation, with engagement playing a pivotal role in treatment success and satisfaction. However, suboptimal engagement can lead to challenges such as not initiating treatment, missed appointments, medication errors, dropping out and heightened stress levels, all of which may adversely affect clinical outcomes.\n\nRecent advancements in Artificial Intelligence (AI) and Machine Learning (ML) have revolutionized healthcare, offering innovative solutions for personalized patient care. In IVF, AI-ML models hold the potential to enhance patient engagement by delivering tailored communication, reminders, and educational support, but also improved prognostication by providing personalized and accurate predictions of treatment outcomes. These capabilities enable patients to make more informed decisions and enhance their adherence to treatment protocols.This protocol outlines a prospective evaluation of an AI-ML model, specifically the Univfy PreIVF report, developed to improve patient engagement in IVF care. Recently, a retrospective, multicenter study reported improved IVF utilization rates among patients counselled using the Univfy PreIVF Report. The current study will prospectively assess the model's effectiveness in addressing individual patient needs and creating a supportive treatment environment. Specifically, this study will measure adherence to providers' recommendation of treatment protocols. By analyzing the impact of these interventions, this research aims to provide robust evidence for the integration of AI-ML technologies in reproductive medicine, paving the way for broader implementation and improved patient outcomes.",[105,106],"Infertility (IVF Patients)","Artificial Intelligence (AI)",[108,109,110,111],"IVF","Artificial intelligence","counselling","Conversion rate","2026-02-20",{"date":114,"type":47},"2026-02-23",{"date":116,"type":47},"2025-06-11",{"date":51,"type":22},{"name":53,"class":54},{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":134,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":138,"locationsCount":55},"100539695","assessing-the-convenience-of-natural-proliferative-phase-frozen-embryo-transfer-100539695","NCT06307184","Assessing the Convenience of Natural Proliferative Phase Frozen Embryo Transfer","Assessing the Convenience of Natural Proliferative Phase Frozen Embryo Transfer: an Ambispective Cohort Study","Inclusion Criteria:\n\n* Endometrial thickness ≥ 7 mm on the day of starting progesterone-based luteal phase support (LPS)\n* Serum progesterone levels \\\u003C1.5 ng\u002Fml on the day of starting progesterone-based LPS\n* LPS with micronized progesterone 400mg b.i.d.\n* Regular cycles (\\>24 days, ≤ 38 days)\n* IVF\u002FICSI with donated oocytes\n* Single blastocyst stage embryo transfer\n* First or second embryo transfer from the same cohort\n\nExclusion Criteria:\n\n* Use of exogenous ovarian stimulation during FET\n* Untreated hydrosalpinx, polyp, submucous myomas or severe adenomyosis\n* Recurrent pregnancy loss (≥ 3 previous pregnancy losses)\n* Recurrent implantation failure with embryos from oocyte donation (≥ 3 previous failed embryo transfers)\n* Personalized initiation of exogenous progesterone according to a previous endometrial receptivity assay test","49 Years",{"count":128,"type":22},530,"This study will assess the convenience of the natural proliferative phase frozen embryo transfer (NPP-FET) in terms of number of number of appointments needed before cycle scheduling.",[131],"Frozen Embryo Transfer",[81,75,36,133],"Pregnancy",{"date":114,"type":47},{"date":136,"type":47},"2024-02-23",{"date":90,"type":22},{"name":53,"class":54},""]